|
US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
US6858617B2
(en)
|
1998-05-26 |
2005-02-22 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
ES2221426T3
(es)
*
|
1998-08-20 |
2004-12-16 |
Smithkline Beecham Corporation |
Nuevos compuestos de triazol sustituidos.
|
|
US6548503B1
(en)
|
1998-11-04 |
2003-04-15 |
Smithkline Beecham Corporation |
Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
|
|
EP2298311B1
(en)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
CA2366932C
(en)
|
1999-04-15 |
2009-08-25 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
US6759410B1
(en)
*
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
|
DE60023025T2
(de)
|
1999-11-23 |
2006-07-13 |
Smithkline Beecham Corp. |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
|
|
ES2230171T3
(es)
|
1999-11-23 |
2005-05-01 |
Smithkline Beecham Corporation |
Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
|
|
JP2003514900A
(ja)
|
1999-11-23 |
2003-04-22 |
スミスクライン・ビーチャム・コーポレイション |
ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
|
|
CA2397661C
(en)
*
|
2000-03-01 |
2012-01-03 |
Janssen Pharmaceutica N.V. |
2,4-disubstituted thiazolyl derivatives
|
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
PE20020506A1
(es)
*
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
|
AU2002246855B2
(en)
*
|
2000-10-23 |
2005-12-22 |
Smithkline Beecham Corporation |
Novel compounds
|
|
ES2257461T3
(es)
|
2000-12-21 |
2006-08-01 |
Bristol-Myers Squibb Company |
Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
WO2002100405A1
(en)
|
2001-06-11 |
2002-12-19 |
Vertex Pharmaceuticals Incorporated |
Isoquinoline inhibitors of p38
|
|
HN2002000156A
(es)
|
2001-07-06 |
2003-11-27 |
Inc Agouron Pharmaceuticals |
Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
|
|
GB0124938D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124931D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124932D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124941D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124936D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124933D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124934D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124939D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
PT1466912E
(pt)
*
|
2002-01-18 |
2013-06-28 |
Astellas Pharma Inc |
Derivado de 2-aciloaminotiazol ou seu sal
|
|
DK1478358T3
(da)
|
2002-02-11 |
2013-10-07 |
Bayer Healthcare Llc |
Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
|
|
ATE529406T1
(de)
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
|
CN100369898C
(zh)
*
|
2002-02-12 |
2008-02-20 |
史密丝克莱恩比彻姆公司 |
用作p38抑制剂的烟酰胺衍生物
|
|
PL219736B1
(pl)
*
|
2002-04-23 |
2015-07-31 |
Bristol Myers Squibb Co |
Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie
|
|
WO2003105840A2
(en)
*
|
2002-06-17 |
2003-12-24 |
The Pennsylvania State Research Foundation |
Sphingosine kinase inhibitors
|
|
AU2003245989A1
(en)
|
2002-07-09 |
2004-01-23 |
Boehringer Ingelheim Pharma Gmbh And Co. Kg |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
|
CA2755297A1
(en)
|
2003-02-10 |
2004-08-26 |
Vertex Pharmaceuticals Incorporated |
Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
|
|
GB0308185D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308186D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308201D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
MXPA05013075A
(es)
*
|
2003-06-03 |
2006-03-17 |
Novartis Ag |
Inhibidores de p-38 basados en heterociclo de 5 miembros.
|
|
PL1663978T3
(pl)
|
2003-07-23 |
2008-04-30 |
Bayer Healthcare Llc |
Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
|
|
GB0318814D0
(en)
*
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
|
US7244441B2
(en)
*
|
2003-09-25 |
2007-07-17 |
Scios, Inc. |
Stents and intra-luminal prostheses containing map kinase inhibitors
|
|
WO2005032551A1
(en)
*
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
|
|
GB0402143D0
(en)
*
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
US20080051416A1
(en)
*
|
2004-10-05 |
2008-02-28 |
Smithkline Beecham Corporation |
Novel Compounds
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
AU2006229995A1
(en)
*
|
2005-03-25 |
2006-10-05 |
Glaxo Group Limited |
Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
|
|
MY145281A
(en)
*
|
2005-03-25 |
2012-01-13 |
Glaxo Group Ltd |
Novel compounds
|
|
AU2006244203B2
(en)
*
|
2005-05-09 |
2012-05-03 |
Achillion Pharmaceuticals, Inc. |
Thiazole compounds and methods of use
|
|
WO2006127678A2
(en)
*
|
2005-05-23 |
2006-11-30 |
Smithkline Beecham Corporation |
Inhibition of p38 mark for treatment of obesity
|
|
GB0512429D0
(en)
*
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
|
IL169855A
(en)
*
|
2005-07-25 |
2014-05-28 |
Elta Systems Ltd |
A system and method for locating a receiver location
|
|
WO2007013830A1
(en)
|
2005-07-26 |
2007-02-01 |
Portela & Ca. S.A. |
Nitrocatechol derivatives as comt inhibitors
|
|
NZ570835A
(en)
*
|
2006-03-08 |
2011-11-25 |
Achillion Pharmaceuticals Inc |
Substituted aminothiazole derivatives with anti-HCV activity
|
|
EP1845097A1
(en)
*
|
2006-04-10 |
2007-10-17 |
Portela & Ca., S.A. |
Oxadiazole derivatives as COMT inhibitors
|
|
ES2452032T3
(es)
*
|
2006-08-08 |
2014-03-31 |
Akarx, Inc. |
Composiciones y métodos para aumentar los niveles de plaquetas de la sangre en humanos
|
|
DK2481410T3
(en)
*
|
2007-01-31 |
2016-10-24 |
Bial - Portela & Ca S A |
Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
|
|
CA2681420A1
(en)
*
|
2007-03-20 |
2008-09-25 |
Cadila Pharmaceuticals Limited |
P38 inhibitors
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
EA200901573A1
(ru)
*
|
2007-05-22 |
2010-04-30 |
Ачиллион Фармасьютикалз, Инк. |
Гетероарилзамещенные тиазолы
|
|
EP2259777A2
(en)
*
|
2008-02-28 |
2010-12-15 |
BIAL - Portela & Ca., S.A. |
Pharmaceutical composition for poorly soluble drugs
|
|
BRPI0908731A2
(pt)
|
2008-03-17 |
2017-05-16 |
Bial - Portela & C A S A |
formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
|
|
US8106209B2
(en)
*
|
2008-06-06 |
2012-01-31 |
Achillion Pharmaceuticals, Inc. |
Substituted aminothiazole prodrugs of compounds with anti-HCV activity
|
|
SG172160A1
(en)
|
2008-12-17 |
2011-07-28 |
Scripps Research Inst |
Generation and maintenance of stem cells
|
|
EP2396302A2
(en)
*
|
2009-02-13 |
2011-12-21 |
Vertex Pharmceuticals Incorporated |
Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides)
|
|
CN102448444B
(zh)
|
2009-04-01 |
2016-05-25 |
巴尔-波特拉及康邦亚股份有限公司 |
包括硝基儿茶酚衍生物的药物制剂及其制备方法
|
|
PT2413913T
(pt)
*
|
2009-04-01 |
2022-06-09 |
Bial Portela & Ca Sa |
Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar
|
|
WO2011019990A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Eisai, Inc. |
Use of e5501 for stimulating platelet production
|
|
US8507499B2
(en)
|
2010-12-06 |
2013-08-13 |
Confluence Life Sciences, Inc. |
Substituted indole/indazole-pyrimidinyl compounds
|
|
DK2648516T3
(da)
|
2010-12-06 |
2019-01-02 |
Aclaris Therapeutics Inc |
Substituerede pyridinon-pyridinylforbindelser
|
|
US8563558B2
(en)
|
2010-12-06 |
2013-10-22 |
Confluence Life Sciences, Inc. |
Substituted pyridine urea compounds
|
|
US9359300B2
(en)
|
2010-12-06 |
2016-06-07 |
Confluence Life Sciences, Inc. |
Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
|
|
US20140045900A1
(en)
|
2011-02-11 |
2014-02-13 |
Bial-Portela & Ca, S.A. |
Administration regime for nitrocatechols
|
|
US9056110B2
(en)
|
2011-12-06 |
2015-06-16 |
Confluence Life Sciences, Inc. |
Substituted pyrimidinone-phenyl-pyrimidinyl compounds
|
|
US9126988B2
(en)
|
2011-12-13 |
2015-09-08 |
Bial—Portela & Ca, S.A. |
Intermediate for preparing a catechol-O-methyltransferase inhibitor
|
|
US20150104870A1
(en)
|
2012-04-27 |
2015-04-16 |
Keio University |
Neuronal differentiation promoter
|
|
KR102313515B1
(ko)
|
2013-06-07 |
2021-10-14 |
어클라리스 쎄라퓨틱스, 인코포레이티드 |
메틸/플루오로-피리디닐-메톡시 치환된 피리디논-피리디닐 화합물 및 플루오로-피리미디닐-메톡시 치환된 피리디논-피리디닐 화합물
|
|
WO2016083863A1
(en)
|
2014-11-28 |
2016-06-02 |
Bial - Portela & Ca, S.A. |
Medicaments for slowing parkinson's disease
|
|
DK3368052T3
(da)
|
2015-10-27 |
2022-03-14 |
Childrens Hospital Med Ct |
Anvendelse af mapk-hæmmere for at nedbringe tabet af hæmatopoietiske stamceller under ex vivo-dyrkning og -genmanipulation
|
|
US20190060286A1
(en)
|
2016-02-29 |
2019-02-28 |
University Of Florida Research Foundation, Incorpo |
Chemotherapeutic Methods
|
|
ES2927715T3
(es)
|
2017-10-05 |
2022-11-10 |
Fulcrum Therapeutics Inc |
Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
|
|
EP3773579A4
(en)
|
2018-03-26 |
2022-03-09 |
Clear Creek Bio, Inc. |
COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
|
|
RU2709496C1
(ru)
*
|
2019-08-01 |
2019-12-18 |
Марат Феликсович Фазылов |
Способ получения аватромбопага
|
|
US12076315B2
(en)
|
2020-03-20 |
2024-09-03 |
Clear Creek Bio, Inc. |
Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
|
|
IL296054A
(en)
|
2020-03-27 |
2022-10-01 |
Aclaris Therapeutics Inc |
Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
|
|
IL305573A
(en)
|
2021-03-15 |
2023-10-01 |
Saul Yedgar |
HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES
|